Share this video  

ELCC 2021 | Upfront treatment of ROS1-rearranged NSCLC

Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, discusses how to choose the optimal therapy for the upfront treatment of ROS1-rearranged non-small cell lung cancer (NSCLC). Dr Cappuzzo outlines the potential benefits and limitations of crizotinib, entrectinib and lorlatinib for patients with ROS1-rearranged NSCLC. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter